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Cancers arise from the accumulation of somatic genome muta-
tions, with varying contributions of intrinsic (i.e. genetic pre-
disposition) and extrinsic (i.e. environmental) factors. For the
understanding of malignant clones, precise information about
their genomic composition has to be correlated with morpholog-
ical, clinical and individual features, in the context of the avail-
able medical knowledge.
Rapid improvements in molecular profiling techniques, the ac-
cumulation of large amount of data in genomic alterations in hu-
man malignancies and the expansion of bioinformatic tools and
methodologies have facilitated the understanding of the molec-
ular changes during oncogenesis, and their correlation with
clinico-pathological phenotypes. Far beyond a limited set of
"driver" genes, oncogenomic profiling has identified a large va-
riety of somatic mutations; and whole genome sequencing stud-
ies of healthy individuals have improved the knowledge of heri-
table genome variation.
Nevertheless, main challenges arise from the skewed represen-
tation of individuals from varying population backgrounds in
biomedical studies, and also through the limited extend in which
some cancer entities are represented in the scientific literature.
Content analyses of oncogenomic publications could provide
guidance for the planning and support of future studies aiming
at filling prominent knowledge gaps.
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Introduction
Cancers as genomic diseases. Cancers are based on the
accumulation of genomic mutations, leading to the transfor-
mation of somatic cells into a malignant clone expressing
the characteristic "Hallmarks of Cancer" (1). Different types
of cancers show varying types of overall mutation patterns,
which may allow to identify molecular subsets beyond tra-
ditional diagnostic classifications (2, 3) and can be utilised
for prognostic risk assessment and clinical decision making
(3, 4).
While the majority of mutations emerge during an indi-
vidual’s lifetime ("somatic" mutations), the risk for devel-
oping a malignant disease can be influenced by inherited
("germline") genome variations. Some mutations predispos-
ing to specific malignancies have been identified due to high
penetrance and apparent familial inheritance pattern (5–7).
However, the interaction of multiple genetic variants on life-
time cancer risk are still poorly understood, reflecting part of
the "missing heritability" (8) of complex diseases.
Germline variants may correlate to the population back-
ground of individuals and be associated - by approximation
- with their geographical origin. Although socio-economic
factors differ in their geographic distribution and contribute
to disease incidence and mortality in general, the strong
association of several inherited single nucleotide variations
(SNV) with specific cancers motivates a more thorough
search for a heritable influence on somatic variation patterns.
Differences in the inherited genomic background may be cor-
related to the amount and types of acquired mutations during
cancer development (9, 10), which has implications for un-
derstanding the molecular behaviour of the tumours as well
as on the treatment options for patients (11–13).
Oncogenomic screening techniques. The possibility of
alterations of a "heritable agent" in the etiology of cancer
had been proposed long before the description of DNA as
the molecule of genetic inheritance, but was met with scepti-
cism in its early days, as expressed in this review of Theodor
Boveri’s work from 1914(14)):
... as well as for its impracticability, it is proba-
ble that the hypothesis will not be favorably re-
ceived by the medical profession.
One of the reasons for early scepticism of chromosomal
changes as basis for cancer development was the impracti-
cability to study them in humans. However, the development
of chromosomal preparation and staining techniques lead to
an interest in studying the chromosomal composition of neo-
plastic cells, starting with hematologic malignancies(15, 16)
as well as solid tumors(17, 18). Over the next decades, the
field of cancer cytogenetics produced a huge number of stud-
ies about chromosomal abnormalities in cancer; currently, the
"Mitelman Database of Chromosome Aberrations and Gene
Fusions in Cancer" reports 68,379 individual cases(19).
While cytogenetic banding can describe "phenotypic" chro-
mosomal observations without analysis of the involved se-
quence alterations, these observations could be associated
with mapped positions of tumor associated genes (24) or
guide their identification (25). Major progress came from
the use of sequence-specific probes using in-situ hybridis-
ation (26, 27), especially after the introduction of Fluores-
cence In-Situ Hybridisation (FISH (28, 29)) and the delin-
eation of chromosomal fragments in cancer karyotypes us-
ing chromosomal "painting" techniques (30, 31). However,
analysis by those technologies required access to karyotypes
from dividing cancer cells or was limited to specific measure-
ments, thereby limiting the utility for discovery of unknown
aberrations.
Table 1. Characteristics of different genomic screening techniques.
chromosomal CGH genomic arrays WES WGS
1st application report 1992(20) 1997(21) 2008(22) 2008(23)
resolution chromosomal bands =
few megabases
mostly in the 100kb
range
single bases ( 2% of the
genome)
single bases
target identification surrogate (position) "semidirect" (segmenta-
tion spanning probes)
direct quantitative and
qualitative
direct quantitative and
qualitative
balanced structural no no (exceptions) depending on position yes
available data >20,000 cases through
Progenetix
raw (GEO, arrayEx-
press) & annotated ar-
rayMap data
limited (controlled, e.g.
e.g. TCGA, ICGC)
limited (controlled, e.g.
PCAWG)
predominant data
format
ISCN = static raw; depends on bioin-
formatics
VCF files VCF files
bioinformatics image segmentation,
densitometry
value segmentation,
background subtraction
alignment, base quality
recalibration, variant
calling
alignment, base quality
recalibration, variant
calling
The first whole-genome molecular cytogenetic technology
not requiring access to living tumor cells was Compara-
tive Genomic Hybridisation (CGH(20, 30, 32)), a reverse
in-situ hybridisation technique in which labeled whole-
genomic tumor DNA is hybridised to a matrix of normal hu-
man metaphase chromosomes. CGH represented the semi-
quantitative analysis of DNA along the whole genome and
importantly allowed the use of DNA extracted from a variety
of source materials, including frozen and archival tissue(33,
34). While the spatial resolution of chromosomal CGH
was limited especially regarding genomic deletions(35), the
analysis of genomic imbalances in neoplasias not amenable
to in vitro culture detected unexpected types of genomic
alterations(36–38) and disease-related patterns(39).
A major advancement for hybridisation based genomic pro-
filing was the replacement of the hybridisation substrate by
thousands of defined DNA probes spotted on glass slides.
Such "array" or "matrix" CGH experiments (aCGH(21, 40,
41)) permitted the direct assignment of altered sequences.
Furthermore, oligonucleotide based "SNP"-arrays, developed
for genetic polymorphism profiling(42), were shown to be
suitable for copy number profiling(43) and became the pre-
dominant genome profiling technology in cancer analysis.
In the last decade, "next generation" sequencing technologies
(NGS) have been applied to genome screening experiments
in cancer, both for the analysis of whole genomes (WGS)
as well as for whole exome sequencing (23, 44, 45). In addi-
tion to detecting single nucleotide variations (SNV) and other
spatially limited sequence variants, the read data from NGS
analyses can be used to derive structural variation data, such
as regional copy number imbalances (46, 47).
Bioinformatics in genome screening. Since the rapidly
accumulating biological data is both complex and extensive,
bioinformatic procedures are required as enabling technolo-
gies for data processing, warehousing and annotation as well
as the biological interpretation of observations and measure-
ments. Over the last decades, specialised areas of bioin-
formatics have emerged with focus on, for instance, image
analysis, data visualization, systems biology, text mining and
"multi-omics", with major repercussions for the biomedical
community and the field of personalised health.
With a focus on genomic profiling data (table 1), different
bioinformatics approaches are applied depending on genomic
screening technique and target of the analysis. Whereas hy-
bridisation based technologies have important dependencies
on image analysis and signal segmentation technologies, a
core technique in the processing of NGS data is in the as-
sembly of nucleic acid and protein sequences (48) and map-
ping of those sequences to reference genomes using a vari-
ety of sequence similarity detection algorithms (e.g. Smith-
Waterman, BLAST, Hidden Markov Models). Further meth-
ods, tools and repositories are continuously being created for
the identification and functional assessment of sequence vari-
ants.
Although great advances in cancer profiling data analysis
have been driven by bioinformatics, a main challenge re-
mains in the integration of data from different sources and
technologies. Unfortunately, an extraordinary share of bioin-
formatic efforts has to be diverted towards data integration,
i.e. the mining and harmonisation of molecular and metadata,
from a vast number of different file formats, data interfaces
and annotation styles.
Published Cancer Genome Screening Stud-
ies
In the time since the first application of CGH to screen can-
cer samples for genomic copy number imbalances, a large
amount of oncogenomic studies has been published, both in
case reports as well as in large studies covering more than
1000 samples (49, 50). While the studies considered here
were using molecular-cytogenetic and genome sequencing
based on different technologies and varying sensitivity and
spatial resolution, they all provide a whole-genome read-out
for genomic copy number imbalances without selectively tar-
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Fig. 1. Publication statistics for cancer genome screening studies. The graphic shows our assessment of publications reporting whole-genome screening of cancer samples,
using molecular detection methods(chromosomal CGH, genomic array technologies, whole exome and genome sequencing). For the years 1993-2018, we found 3078
publications reporting 150000 individual samples in single series from 1 to more than 1000 samples. Y-axis and size of the dots correspond to the sample number; the color
codes indicate the technology used.
geting specific genome elements.
For our discussions considering the "Oncogenomic Publica-
tion Landscape" we will focus on studies of whole genome,
molecular screening techniques using tumor DNA as start-
ing material, including chromosomal (cCGH) and array CGH
(aCGH, including single-color oligonucleotide and SNP ar-
rays), as well as whole exome and genome sequencing (WES,
WGS). We will use data from existing repositories to high-
light biases in published cancer genome screening data, both
regarding the representation of disease entities as well as with
view of the geographic provenance. For this discussion we
will consider the different technologies as "equivalent by in-
tent" - i.e. whole genome cancer variation profiling - and
not with respect to differences in the detection sensitivity or
added data qualities beyond structural variation profiling.
Most of the following observations are based on data col-
lected for the Progenetix (progenetix.org (51)) and arrayMap
(arraymap.org (52)) resources. Although these curated data
repositories cannot provide an exhaustive image of all re-
search in the area, the massive amount of data accumulated
there can deliver a representative snapshot of the field, to en-
courage discussions about study targets and data trajectories.
The Progenetix website was established in 2001 (51), to col-
lect and represent data from published CGH studies for com-
parative meta-analyses of genomic copy number profiles. In
identifying data suitable for the resource, over the years a
main feature became the general tracking of publications
about cancer genome screening studies, independent of the
accessibility of the raw data itself. Data attributes for each
publication registered in Progenetix and relevant for the dis-
cussions are e.g. the number of cancer samples per techno-
logical category (cCGH, aCGH, WES, WGS); the geographic
provenance of the samples (approximated by the location of
the study’s corresponding author) as well as the "cancer type"
reported. Where available, sample specific copy number im-
balance data is collected and represented in various formats
(53).
In contrast to the Progenetix resource, the arrayMap cancer
genome repository represents genome profiling data through
mining and re-processing of genomic array data, currently
including more than 260 platform types with the minimum
requirement of whole-genome probe level representation. As
in the case for Progenetix, main features are data curation and
annotation in standardised formats, as well as the graphical
representation of genome variation data (52).
While the main reason for individual genome screening anal-
yses is the discovery of genome variants without a priori tar-
get selection, an added benefit lies in the possibility to assem-
ble large datasets for meta-analyses of cancer related genome
variant frequencies and patterns. Such datasets enable com-
parative studies of driver gene involvement (e.g. MYCN,
BCL2, TP53, HER2, CDKN2A/B, or BRAF) across differ-
ent cancer types. Also, since many potential gene targets in
genomic regions with recurring CNA across cancer types still
remain to be identified, events such as the recurring occur-
rence of focal genome alterations have been argued to repre-
sent consequences of strong selection on limited structural re-
arrangement events during cancer evolution (54, 55) and can
be used to pinpoint candidate oncogene involvement based
on statistical analyses (56).
The integration of cancer genomic data across studies can
help to define the genetic landscape of different cancer types.
As example, in a study combining genomic data of breast
and colorectal cancers, 189 genes were identified to con-
tribute to neoplastic processes. These genes were previously
unknown to be modified in cancers but they reveal certain
cancer-specific patterns by the integrative analysis (57). This
kind of integrative approach is beneficial not only to find
novel gene targets, but also to discover the general patterns
across various cancer types.
As resource for the identification of existing reports for spe-
cific cancer types as well as for the assembly of meta-analysis
studies, the Progenetix resource currently provides metadata
about more than 3000 articles published between 1993 and
2018, representing 36496, 102009, 7023 and 3343 individual
cancer samples analysed by cCGH, aCGH, WES and WGS,
respectively. Figure 1 displays the temporal distribution of
these publications, with indications for the number of pre-
sented samples and used technologies. While these num-
bers have a certain temporal lag - both due to delay between
data production and publication and delays in identification
and annotation of the respective articles - one can observe
the general trends to move towards newer technologies and
higher sample numbers per published study, with NGS based
studies increasingly replacing hybridisation based analyses
(so far with lower, but increasing, numbers per study).
Representation of diagnostic classes. While the overview
of the oncogenomic publication space gives some indication
about the overall amount of data being produced in research
studies, these estimates do not provide information about
data produced for different cancer types. For an approxima-
tion of the availability of diagnosis-matched genome profiles,
one can utilise resources which provide per sample metadata,
with annotations mapped to uniform classification systems.
Such resources can consist of collaborative projects, such as
The Cancer Genome Analysis project (TCGA (58)) or the In-
ternational Cancer Genome Consortium (ICGC (59)), where
many individual research groups contribute molecular profil-
ing and metadata of different tumor types in a coordinated
fashion, or in curated data resources.
For our arrayMap resource (arraymap.org(52)) we
utilise different primary data sources such as EBI’s
arrayExpress(60), publication supplements and user pro-
vided data. However, arrayMap data chiefly reflects the
content of NCBI’s GEO resource(61), for cancer data
sets from suitable genomic array platforms. To date, 267
different platforms and 901 experimental series are available
for CNA arrays. As result of the continuous data integration
performed through a semi-automated data processing and
annotation pipeline(52), at this time a total of 250 mor-
phologies from 94 distinct topographies have been annotated
according to ICD-O 3(62)).
As seen in figure 2 the vast majority of the samples from ar-
0 2500 5000 7500 10000
C42
C50
C71
C34
C18
C77
C56
C16
C64
C44
C61
C47
C15
C22
C49
C10
C53
C67
C76
C54
C25
C06
C40
C20
C70
C74
C72
C38
C68
C80
C41
C62
C11
C69
C17
C55
C08
C73
C01
C75
C32
C57
C51
C24
C63
C09
C07
C14
C65
C48
Number of samples in ArrayMap database
Cervix Uteri
Bladder
Other and Ill-Defined Sites
Corpus Uteri
Pancreas
Mouth, NOS
Bones, Joints and Articular Cartilage of Limbs
Rectum
Meninges
Adrenal Gland
Spinal Cord, Cranial Nerves, Other Parts of Central Nerv. System
Heart, Mediastinum, and Pleura
Other Urinary Organs
Unknown Primary Site
Bone, NOS
Testis
Nasopharynx
Eye and Adnexa
Small Intestine
Uterus, NOS
Other and Unspecified Major Salivary Glands
Thyroid Gland
Base of Tongue
Other Endocrine Glands and Related Structures
Larynx
Other and Unspecified Female Genital Organs
Vulva
Other and Unspecified Parts of Biliary Tract
Other and Unspecified Male Genital Organs
Tonsil
Parotid Gland
Other and Ill-Defined Sites in Lip, Oral Cavity and Pharynx
Renal Pelvis
Retroperitoneum and Peritoneum
Hematopoietic System
Breast
Brain
Bronchus and Lung
Colon
Lymph Nodes
Ovary
Stomach
Kidney
Skin
Prostate Gland
Peripheral nervs incl. Autonomous
Esophagus
Liver and Intrahepatic Bile Ducts
Connective, Subcutaneous and Other Soft Tissues
Oropharynx
Fig. 2. Distribution of the 50 most studied cancer times based on entities repre-
sented in arrayMap by ICD-O-3 topography (i.e. organ site)
10
0
10
00
10
00
0
2004 2006 2008 2010 2012 2014
Year
Cu
m
ula
tiv
e 
nu
m
be
r o
f s
am
ple
s i
n 
Ar
ra
yM
ap
 d
at
ab
as
e
C42
C50
C71
C34
C18
C77
C56
C16
C64
C44
C61
C47
C15
C22
C49
ICD-O 
Topography
Fig. 3. Cumulative number of samples of the 15 most represented cancer types by
ICD-O Topography codes in the arrayMap database, over a 10 year period (sample
numbers in logarithmic scale)
rayMap are from hematologic neoplasias, breast cancer, brain
tumors, lung and bronchus carcinomas and colorectal cancers
with a representation of 25 (20 + 5 for other NHL), 16, 11,
8 and 5% respectively. When including the year of publi-
cation, we observe that the relative contributions are approxi-
mately maintained within the 10 year period (figure 3). While
the granularity of diagnostic assignments may differ between
studies, it is striking that more than half of the data is derived
from 4% of 94 registered cancer sites.
A selection bias regarding cancer types also is apparent when
comparing study representation (arrayMap and TCGA) with
the respective incidences. While breast cancer cases repre-
sent 15.3% of all cancers (63), in arraymap 15.8% (9.70%
TCGA) of samples were identified as representing a type of
breast carcinoma. However, prostate cancer accounting for
9% of all new cases is underrepresented with only 2.21%
(4.41%) of study samples. Bladder cancer, which accounts
for 4.7% of all new cancer cases, has 1.16% (3.66%) of the
Fig. 4. The map displays the geographic distribution (by corresponding author) of the 102225 genomic array, 36747 chromosomal CGH and 7212 whole genome/exome
based cancer genome datasets. The numbers are derived from the 3103 publications registered in the Progenetix database.
sample representation; thyroid cancer 3.1% incidence with
0.16% (4.48%) samples; larynx carcinoma with 0.8% inci-
dence and 0.05% of samples (1.11% TCGA).
Moreover, whereas some of the most studied cancers have
low mortality rates such as breast with almost 90% survival
after 5 years, special mention should be made for those enti-
ties underrepresented and with high mortality. For instance,
pancreas cancers has 0.75% of samples in arraymap (1.63%
TCGA) but 3.2% of all new cases with a 8.5% 5 years sur-
viving rate. While esophagus cancer is proportionally well
represented (1.70% / 1.63% of samples for 1% of all new
cancers), it remains poorly understood with the 5 years sur-
vival rate still at 19.2%.
Overall, cancer genome publications reflect the preferred
analysis of frequent cancers with some apparent biases, while
being limited in the representation of rare tumor types. Mul-
tiple factors could explain biases in cancer type selections:
lack of general interest and major problematic assembly of
biosamples for rare cancer types; allocation of research fund-
ing for specific cancer types (e.g. breast cancer) due to public
perception and advocacy, lack of availability of tissue sam-
ples due to technical difficulties in sample extraction and pro-
cessing, or ethical and legal implications regarding patient
privacy in sample sharing for genomic analysis (64–66). To
relieve these disparities, global and efficient actions should
be taken. While the current tendency is indeed to study can-
cer types with high incidences, the study of rare entities could
dramatically increase our knowledge of cancer biology.
Geographies of Published Studies. A number of stud-
ies remark on disparities in cancer incidence, prevalence and
mortality related to ethnicity and geographic origin (67, 68).
Two general classes of factors have been found to contribute
to these disparities: A) environmental factors through differ-
ent types and levels of exposure related to local or regional
geographical origin, and B) population-specific variation in
genomic variants with influence on heritable contributions on
cancer development.
Although, many studies relate the influence of geographic
patterns incidences with environmental factors such as pollu-
tion levels, intensity of UV radiation or exposure to infectious
agents (67), the contribution of population-specific biases in
cancer promoting genome variants is less well defined. Some
relevant studies in the area have shown the BRCA1 gene as a
population specific bias in some homogeneous groups com-
pared to outbread reference populations (69). In the assembly
of a meta-resource for oncogenomic publications, the con-
tact information of the corresponding authors represents an
important piece of information, e.g. for facilitating the con-
tacting of study authors by the resource’s users, for followup
questions or access to detailed study information or source
data. However, this information can also be used as proxy to
provide quantitative representation of study content with re-
lation to geographic provenance, leading to some interesting
observations.
The geographic origin mapping of the more than 3000 publi-
cations represented in the Progenetix article registry showed
large biases regarding the provenance of the published data
(table 2). While the overall preponderance of studies from
Europe (1619) and North America (833) could be expected,
the near complete lack of cancer genome screening studies
from the African continent was unexpected.
Since cancer development can be influenced by population-
related inherited genome variants as well as extrinsic factors
related to local environmental exposure and socio-cultural
practices, it is of paramount importance to include geolo-
cation metadata in the assessment of molecular profiling.
However, the real impact of factors correlated to geographic
provenance can only be assessed with the availability of suf-
ficient, representative data for a large range of geographies,
Table 2. Numbers of publications and associated samples in the Progenetix article
registry, separated for geographic regions.
Pub.
Samples per Technique
(Sub-) Continent
cCGH aCGH WES WGS
3 58 33 0 0 Africa
46 225 1444 303 288 Australia
465 6132 10736 1534 579 East Asia
28 564 1324 45 0 South Asia
31 720 209 0 0 Western Asia
1619 24070 47251 1912 1465 Europe
833 4680 39352 2888 936 North America
29 208 230 2 1 South America
ethnicities and environments.
Focusing on the geographic location of the studies, the ten-
dency is, as expected, for developed countries to provide
the majority of oncogenomic data (Fig. 4). Most of the
published studies are reported from the Europe, the United
States, China, Japan, Australia and the Korean Republic. In
contrast, only very few studies have been reported from Cen-
tral and South Asia as well as South America. However,
most striking is the near complete absence of cancer genome
studies from the African continent, in the accessible litera-
ture. One can assume that these geographic biases reflect
major difficulties in the establishment of technology-driven
research in underdeveloped countries - from lack of training
of scientists, to infrastructure problems for biosample extrac-
tion, expense and availability of reagents and technical equip-
ment as well as computing infrastructure for bioinformatic
processing(70).
A more uniform map of the amount of genomic studies across
the world is of further importance for clinical trials, where the
attention on the genetic variation across ethnic groups could
improve novel therapies and reduce cancer disparities.
GA4GH to the rescue. While the need for more and diverse
studies of cancer genome mutation profiles and their rela-
tion to the underlying personal genomes is increasingly be-
ing realised, a major obstacle in utilising the emerging data
lies in the high degree of fragmentation and "siloing" of the
generated data. Genomics and associated metadata is fre-
quently created as part of research studies with study specific
consent(71) and access restricted to original study collabo-
rators. If mechanisms for outside researchers are in place,
they usually require submission of specific project propos-
als and review through a data access committee (DAC) and
agreement to specific usage conditions. If data then can be
accessed, it is in a variety of genome and metadata formats
which usually have to be normalized to common encodings.
The core mission of the Global Alliance for Genomics and
Health initiative (GA4GH(72)) is to "...enable genomic data
sharing for the benefit of human health". Its members ad-
dress this goal through the improvement of global standards
and the creation of tools to securely share genomic data,
across geographic or institutional boundaries. Formally es-
tablished in 2014 and with and increasing participation of
currently 499 organisational members from 44 countries, the
GA4GH has started to shape the public discourse about the
benefits of genome-driven research for human health appli-
cations, and started to provide guidelines(73), standards and
toolkits to enable secure and ethically responsible data shar-
ing. These activities are based on the the work of different
"work streams", which interact with existing "driver projects"
in the iterative development, testing and implementation of
protocols, standards and toolkits. The driver projects them-
selves - such as the "Beacon"(74) project or the "BRCA
exchange"(75) address particular scientific, technical, regula-
tory or security related aspects of federated access to human
genomes and related metadata. However, while the develop-
ment of protocols, tools an guidelines for the effective shar-
ing of genome-related data is a pre-requisite for widening the
scope and statistical significance of studies in biomedical ge-
nomics, by themselves these efforts alone cannot solve the
skewed generation of genome screening data with respect to
disease representation and REA provenance. Additionally,
having suitable protocols and tools at hand does not guaran-
tee their implementation and use by the providers of the many
institutional or national resource providers. These problems
can only be addressed in an iterative process, involving coor-
dinative work by organizations such as GA4GH in interaction
with national and international policy makers and funders of
scientific projects and research infrastructures.
Conclusions
Continuous efforts into the understanding of tumor biology
have lead to an increasing number of coordinated interna-
tional projects generating oncogenomic data. This progress
has been made possible by the development of genome
screening techniques, supported through the rapid advance-
ment in computational hardware and bioinformatic tools.
Nowadays, the tight integration of bioinformatics can be con-
sidered essential not only for meta-analyses and statistical
studies, but is a necessary element in the execution of all
types of molecular analyses and data management pipelines.
However, the ability to use text mining and other bioinfor-
matics tools to create large surveys of existing genome stud-
ies now allows to observe biases in the data being reported,
both with respect to the representation of tumor entities as
well as in the general lack of data from large fractions of the
world’s populations. Impacts of these biases can be suspected
in the missing opportunities for insights into particular onco-
genetic mechanisms in rare cancer types, and the failure to
fulfil the promises "Precision Medicine" to those patients.
The other type of bias discussed here is the highly lim-
ited representation of many human populations - particu-
larly from Africa - in publications reporting data from can-
cer genome screening analyses. The resulting lack of ethnic
diversity will still be a barrier in trying to elucidate molecu-
lar events related to specific population backgrounds, thereby
possibly missing out on specific therapeutic targets. These
biases are not only limited to cancer, with recent data show-
ing that more that 50% of all reported genome variants in
the Genome Aggregation Database (gnomAD) are based on
European ancestry(76).
Besides the well known impact of major socio-economic fac-
tors, efforts towards understanding of disparities in global
cancer incidences and prognostic trajectories should also be
directed with the characterisation of differences in genetic
variation patterns - both inherited polymorphisms and so-
matic variants in cancer genomes - for large numbers of pa-
tients from a variety of population backgrounds. Moreover,
researchers should increasingly direct their attention towards
rare cancer entities from which the knowledge would dramat-
ically increase in benefit of personalised medicine. Here, one
can argue that the limited number of cancer types studied and
the low diversity of targeted populations should be addressed
through the allocation of financial resources and support of
international collaborative efforts.
One important aspect of a truly global understanding of ev-
ery aspect of the impact of inherited and somatic variations
on cancer biologies, clinical prognostications and targeted in-
terventions will be to facilitate data access beyond the current
localised data silos and individual publications with, at best,
highly fragmented but frequently non-existing access to ge-
nomic and associated metadata. Here, the Global Alliance for
Genomics and Health provides a leading effort towards the
better access to health related data, beyond individual studies
and localised repositories, towards a global network of inter-
acting standards and resources.
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